CAR T Therapy Cost Control With Laurence Cooper, M.D., Ph.D.
Business Of Biotech
00:00
Zaphron's Vision for Rapid Manufacturing
Cooper: There's been a lot of conversation around the supply chain and availability in the wake of COVID-19. It sounds to me like this approach is a bit more insulated from those potential global disruptions down the road as well. Cooper: Zaphron wants to treat patients big and small. And we're not a meat-to-company. We have ideas that are unique, that are born from wisdom of being in that room with that cancer patient.
Play episode from 33:20
Transcript
